KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)
Compound 25: A mutant KRASG12C allosteric covalent inhibitor
"compound 25"
mutant KRASG12C allosteric covalent inhibitor orally efficacious in XG model from optimization of literature starting point J. Med. Chem. Feb. 5, 2020 AstraZeneca, Cambridge, UK